Close

Leukemia

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Leukemia, generally refers to cancers of the WBCs. In America, more than forty thousand people are diagnosed with leukemia each year. It arises in the bone marrow, the soft, sponge-like material inside long bones of four limbs, where blood cells form. Under healthy circumstance, mature blood cells migrate from bone marrow into the blood circulatory system, but in the bone marrow of leukemia patient, some white blood cells divide too fast and cannot get mature as a result of incorrectly development, which finally crowd out the normal, healthy ones. As WBCs play a vital role in protecting body from microbe infection and abnormal cells invasion, the loss of WBCs leads body into a dangerous situation. Gene mutation, chromosome fraction rearrangement, and the exposure to radiation, chemicals are the possible causes of this disease. Meanwhile, heredity and virus infection are also linked to the development of leukemia.

Depending on the type and the growth rate of cell affected, people classify leukemia into four groups:

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.